Table 1.

Echocardiographic data from saline-injected controls and MCT-injected rats receiving oral vehicle (DMSO) or LASSBio-1359 (50 mg·kg⁻¹) for 14 days

	Control	MCT	MCT + vehicle	MCT + LASSBio-1359
Pulmonary artery acceleration time, ms	44.2 ± 0.7	24.8 ± 1.6*	25.5 ± 1.3*	39.8 ± 2.0†‡
LV cardiac output, mL·min−1	127.4 ± 1.9	80.0 ± 7.0*	77.4 ± 2.1*	126.6 ± 5.7†‡
RV wall thickness, cm	0.10 ± 0.02	0.16 ± 0.01*	0.15 ± 0.09*	0.11 ± 0.03†‡
RV area, mm2	9.6 ± 0.4	21.9 ± 1.2*	23.4 ± 1.4*	13.8 ± 1.0*†‡
LV area, mm2	21.3 ± 2.1	16.4 ± 0.9	20.5 ± 1.5	19.7 ± 1.9
Pulmonary artery diameter, cm	0.29 ± 0.01	0.38 ± 0.01*	0.41 ± 0.01*	0.31 ± 0.01†‡
Heart rate, bpm	332.0 ± 1.4	321. ± 0.9	334.2 ± 1.8	329.4 ± 0.9
LV stroke volume, mL	0.23 ± 0.30	0.11 ± 0.50*	0.13 ± 0.80*	0.24 ± 1.20†‡

All values are mean ± SEM, n = 6 per group.

LV, left ventricle; RV, right ventricle.

^*P < 0.05 versus control;

^†P < 0.05 versus MCT;

^‡P < 0.05 versus MCT + vehicle (DMSO).